Genome Medicine (Aug 2022)

A genetic model for central chondrosarcoma evolution correlates with patient outcome

  • William Cross,
  • Iben Lyskjær,
  • Tom Lesluyes,
  • Steven Hargreaves,
  • Anna-Christina Strobl,
  • Christopher Davies,
  • Sara Waise,
  • Shadi Hames-Fathi,
  • Dahmane Oukrif,
  • Hongtao Ye,
  • Fernanda Amary,
  • Roberto Tirabosco,
  • Craig Gerrand,
  • Toby Baker,
  • David Barnes,
  • Christopher Steele,
  • Ludmil Alexandrov,
  • Gareth Bond,
  • Genomics England Research Consortium,
  • Paul Cool,
  • Nischalan Pillay,
  • Peter Van Loo,
  • Adrienne M. Flanagan

DOI
https://doi.org/10.1186/s13073-022-01084-0
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background Central conventional chondrosarcoma (CS) is the most common subtype of primary malignant bone tumour in adults. Treatment options are usually limited to surgery, and prognosis is challenging. These tumours are characterised by the presence and absence of IDH1 and IDH2 mutations, and recently, TERT promoter alterations have been reported in around 20% of cases. The effect of these mutations on clinical outcome remains unclear. The purpose of this study was to determine if prognostic accuracy can be improved by the addition of genomic data, and specifically by examination of IDH1, IDH2, and TERT mutations. Methods In this study, we combined both archival samples and data sourced from the Genomics England 100,000 Genomes Project (n = 356). Mutations in IDH1, IDH2, and TERT were profiled using digital droplet PCR (n = 346), whole genome sequencing (n=68), or both (n = 64). Complex events and other genetic features were also examined, along with methylation array data (n = 84). We correlated clinical features and patient outcomes with our genetic findings. Results IDH2-mutant tumours occur in older patients and commonly present with high-grade or dedifferentiated disease. Notably, TERT mutations occur most frequently in IDH2-mutant tumours, although have no effect on survival in this group. In contrast, TERT mutations are rarer in IDH1-mutant tumours, yet they are associated with a less favourable outcome in this group. We also found that methylation profiles distinguish IDH1- from IDH2-mutant tumours. IDH wild-type tumours rarely exhibit TERT mutations and tend to be diagnosed in a younger population than those with tumours harbouring IDH1 and IDH2 mutations. A major genetic feature of this group is haploidisation and subsequent genome doubling. These tumours evolve less frequently to dedifferentiated disease and therefore constitute a lower risk group. Conclusions Tumours with IDH1 or IDH2 mutations or those that are IDHwt have significantly different genetic pathways and outcomes in relation to TERT mutation. Diagnostic testing for IDH1, IDH2, and TERT mutations could therefore help to guide clinical monitoring and prognostication.

Keywords